Public prices involving Bristol Myers Squibb
- Licence to Bristol Myers Squibb of certain multimodal records from Tempus AI's de-identified oncology dataset, with access to Tempus's Lens analysis software and related data analysis and research services, term to 31 December 2031
A realised licence in the licensor's filing, signed 14 October 2026 under the 2018 master services agreement. The price also buys software access and services, so it is not a data-only price. BMS may end it on 12 months' notice and a 'substantial termination fee'. It sits beside the $55 million Pathos neurology licence in the same filing ($100 per delivered record), which BMS uses with Pathos; together the two are $192.5 million over about five years.
The payer's own page, Tempus AI, Inc. (SEC Form 8-K, Item 8.01, 23 October 2026)
$137.5 million in aggregate fixed payments over the term, invoiced quarterlytotal fixed payments over the term (about five years)
Licensing deals
- Oct 2026Tempus AI to Bristol Myers Squibb$138M
Not stated
In the same deals and cases
Cite this
AIData.Broker, “Bristol Myers Squibb in the AI training data market”, reviewed 23 Oct 2026. https://aidata.broker/companies/bristol-myers-squibb
Free to reuse under CC BY 4.0 if you credit AIData.Broker and link to this page. Each row names the publication that stated it, and words quoted from a source keep that source's own terms.